Feb 26 (Reuters) - Aixtron SE ::DGAP-NEWS: AIXTRON: 2018 TARGETS EXCEEDED / STRATEGIC REALIGNMENT SUCCESSFULLY COMPLETED / OPERATING BUSINESS IMPRESSES WITH STRONG GROWTH.DGAP-NEWS: AIXTRON: 2018 TARGETS EXCEEDED / STRATEGIC REALIGNMENT SUCCESSFULLY COMPLETED / OPERATING BUSINESS IMPRESSES WITH STRONG GROWTH.ORDER INTAKE ROSE TO EUR 302.5M (+15%) COMPARED TO PREVIOUS YEAR.REVENUES UP YEAR-ON-YEAR (ADJUSTED) TO EUR 268.8M (+40%).FOR 2019, COMPANY EXPECTS A STABLE TO SLIGHTLY GROWING REVENUE DEVELOPMENT COMPARED TO 2018.CUSTOMERS ARE RELUCTANT TO MAKE INVESTMENT DECISIONS IN OPTOELECTRONICS AND FURTHER DEVELOPMENT FOR SECOND HALF OF 2019 IS DIFFICULT TO ANTICIPATE.OPTIMISTIC ABOUT LONG-TERM PROSPECTS FOR DEMAND FOR MOCVD SYSTEMS FOR PRODUCTION OF LASERS FOR APPLICATIONS IN 3D SENSOR TECHNOLOGY OR OPTICAL DATA TRANSMISSION AS WELL AS FOR LED APPLICATIONS.MANAGEMENT EXPECTS TO RECEIVE ORDERS FOR 2019 FINANCIAL YEAR IN A RANGE BETWEEN EUR 220M AND EUR 260M.DIFFICULTY IN QUANTIFYING SIZE OF ANY POSSIBLE OLED ORDER.REVENUES IN A RANGE BETWEEN EUR 260M AND EUR 290M, MANAGEMENT EXPECTS TO ACHIEVE A GROSS MARGIN OF BETWEEN 35% AND 40% AND AN EBIT OF BETWEEN 8% AND 13% OF REVENUES IN 2019.MANAGEMENT ANTICIPATES A FREE CASH FLOW BETWEEN EUR 15M AND EUR 25M FOR 2019.
Full Article
Feb 26 (Reuters) - Aixtron SE ::Q4 SALES 87.9 MILLION EUR.Q4 EBIT 20.8 MILLION EUR.Q4 NET PROFIT 18.2 MILLION EUR.
Full Article
Jan 2 (Reuters) - Bluglass Ltd ::BLUGLASS ENTERS COLLABORATION WITH AIXTRON SE.COLLABORATION TO EVALUATE BLUGLASS' PLASMA CHEMICAL VAPOUR DEPOSITION TECHNOLOGY.
Full Article
Oct 30 (Reuters) - Aixtron SE ::Q3 ORDER INTAKE 76.0 MILLION EUROS, DOWN 0.7 PERCENT FROM Q2, VERSUS. REUTERS POLL AV 70.0 MILLION.Q3 SALES 63.4 MILLION EUROS, UP 15 PERCENT FROM Q2, VERSUS. REUTERS POLL AV 66.0 MILLION.Q3 EBIT 8.7 MLB EUROS, UP 53 PERCENT FROM Q2 VERSUS REUTERS POLL AV 6.45 MILLION.Q3 NET PROFIT 11.7 MILLION.RAISES FULL-YEAR GUIDANCE, NOW SEES EBIT AT 35 - 40 MILLION EUROS.NOW SEES F-Y ORDER INTAKE OF APPROX 290 MILLION EUROS.
Full Article
Oct 24 (Reuters) - Aixtron SE ::DGAP-ADHOC: AIXTRON AND IRUJA CO. LTD. SIGN JOINT VENTURE AGREEMENT / APEVA TO BECOME A COMPLETE OLED DEPOSITION SYSTEM PROVIDER.JOINT VENTURE AGREEMENT BY CO, GERMANY AND IRUJA CO., SOUTH KOREA TO INVEST IN APEVA, CO'S SUBSIDIARY FOR OLED DEPOSITION TECHNOLOGIES.IRUJA WILL OBTAIN AN EQUITY STAKE IN APEVA OF UP TO 20% OVER NEXT FEW YEARS.IRUJA WILL ACT AS A MANUFACTURING PARTNER IN KOREA FOR APEVA.IRUJA TO CONTRIBUTE THEIR AUTOMATION & HANDLING TECHNOLOGY FOR DISPLAY MARKET INTO JV IN STEPS, ALSO MAKING CASH CONTRIBUTIONS.AIXTRON-BASED ON CONTRIBUTIONS FROM BOTH COMPANIES, APEVA WILL BECOME COMPLETE DEPOSITION SYSTEM PROVIDER FOR ORGANIC MATERIAL LAYERS WITHIN OLED STACK..
Full Article
July 26 (Reuters) - Aixtron SE ::RAISES 2018 ORDER INTAKE GUIDANCE TO 260-290 MILLION EUR FROM 230-260 MILLION.NOW SEES 2018 SALES AT 260 MILLION EUR (VERSUS 230-260 MILLION), GROSS MARGIN 40 PERCENT (VERSUS 35-40 PERCENT), EBIT MARGIN 10 PERCENT (VERSUS 5-10 PERCENT).Q2 ORDER INTAKE 75.6 MILLION EUROS, DOWN 4 PERCENT VERSUS Q1, VERSUS REUTERS POLL AVERAGE 74.7 MILLION.Q2 SALES 55.2 MILLION EUROS, DOWN 12 PERCENT VERSUS Q1, VERSUS REUTERS POLL AVERAGE 60.2 MILLION.Q2 EBIT 4.1 MILLION EUROS, DOWN 48 PERCENT, VERSUS REUTERS POLL AVERAGE 4.2 MILLION.Q2 NET PROFIT 3.7 MILLION EUROS, DOWN 70 PERCENT VERSUS Q1.
Full Article
Oct 23 (Reuters) - Aixtron Se :CFIUS approves sale of ALD/CVD memory product line / closing expected in 2017.Investigation resulted in determination that there are no unresolved U.S. National security concerns from CFIUS' perspective for deal.CFIUS approved transaction.
Full Article
June 8 (Reuters) - AIXTRON SE ::DR. FELIX GRAWERT APPOINTED AS A NEW MEMBER OF THE EXECUTIVE BOARD / DR. GRAWERT TO ASSUME HIS POSITION ON OCTOBER 1, 2017 OR EARLIER / DR. SCHULTE AND DR. GRAWERT TO JOINTLY LEAD THE COMPANY .KIM SCHINDELHAUER TO RESUME HIS POSITION AS CHAIRMAN OF SUPERVISORY BOARD.
Full Article
May 25 (Reuters) - AIXTRON SE ::AIXTRON SE TO SELL ITS ALD/CVD MEMORY PRODUCT LINE / THE TRANSACTION IS SUBJECT TO REGULATORY APPROVALS / THE TRANSACTION IS EXPECTED TO CLOSE IN THE SECOND HALF OF 2017.AGREED PURCHASE PRICE IN A RANGE BETWEEN USD 45 MILLION AND USD 55 MILLION WILL BE PAID IN CASH AT CLOSING.TO SELL ALD AND CVD MEMORY PRODUCT LINE, AT AIXTRON, INC. BASED IN SUNNYVALE, CALIFORNIA TO EUGENE TECHNOLOGY INC., A WHOLLY OWNED U.S. SUBSIDIARY OF EUGENE TECHNOLOGY CO., LTD, SOUTH KOREA.EXPECTS THAT THIS TRANSACTION WILL NOT AFFECT FULL YEAR 2017 GUIDANCE WITH ORDER INTAKE AND REVENUES BETWEEN EUR 180 AND 210 MILLION.GUIDANCE INCLUDES CORE BUSINESS AND ALD/CVD BUSINESS UP TO DATE OF SALE.
Full Article
Earnings vs. 
Estimates